Bliss GVS Pharma informs about credit rating
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Bliss GVS Pharma has informed that ICRA vide its letter dated April 08, 2026, bearing ref. no. ICRA/Bliss GVS Pharma Limited/08042026/1 has taken ‘[ICRA]A-(Stable)/ [ICRA]A2+ for Long-term/Short-term - Fund based/Non-fund-based facilities of the Company.
The above information is a part of company’s filings submitted to BSE.
